Abbott Laboratories– tag –
-
Abbott Receives FDA Authorization for Libre Duo 10 Day: World’s First Dual Continuous Glucose and Ketone Monitoring System for Early DKA Warning
Medical Update Online (Abbott) USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day, the world's first dual continuous glucose and ketone monitoring (CGKM) system. This novel bio-wearable provides real-time glucose ... -
Five Key Trends in Diabetes Technology for 2026: Longer-Lasting CGMs, OTC Expansion, and Multi-Biomarker Monitoring Lead Innovation
DiabeticSupplieInc.com Unknown Overview Five major trends are shaping diabetes technology in 2026, including longer-lasting continuous glucose monitoring (CGM) sensors like the FDA-cleared Dexcom G7 15-day system, expanded CGM access for... -
Abbott’s Libre Duo 10-Day System Receives FDA Authorization as First Wearable Continuous Glucose-Ketone Monitor in U.S.
Diabetes Education Services USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System, making it the first wearable device in the U.S. and globally to continuously monitor... -
Abbott Secures Sweeping Injunction Against SiBio’s GS3-R CGM System at Unified Patent Court, Intensifying IP Disputes in Medtech
Facebook USA Overview Abbott Diabetes Care has secured a broad preliminary injunction from the Unified Patent Court (UPC) against SiBio's GS3-R continuous glucose monitoring (CGM) system, effective September 10, 2026. This significant ru... -
FDA Marks New Era in Diabetes Care with First Dual Glucose-Ketone Wearable and OTC Pediatric CGM
FDA News / Health Technology News USA Overview The U.S. FDA has ushered in a new chapter for diabetes technology, authorizing Abbott's Libre Duo as the first wearable device for continuous dual monitoring of glucose and ketones, and clea... -
Abbott’s Libre Duo 10 Day System Receives FDA De Novo Clearance as First Integrated Continuous Glucose-Ketone Monitor
Pharmacy Times USA Overview Abbott's Libre Duo 10 Day system has received FDA De Novo clearance, becoming the first integrated continuous glucose-ketone monitoring (iCGK) system in the U.S. and the world's first wearable device to track ... -
TechRadar Hails ‘Diabetes Breakthrough’: FDA Approves Abbott’s World’s First Dual-Sensor CGM
TechRadar UK Overview TechRadar reported the FDA's approval of Abbott's Libre Duo 10 Day as a 'diabetes breakthrough.' This is the world's first dual-sensor Continuous Glucose Monitoring (CGM) system capable of simultaneously tracking bo... -
Epocrates Explains: Ketone Tracking Integrated into CGM with First-of-its-Kind Wearable, Enhancing Diabetic Ketoacidosis Prevention
Epocrates USA Overview Epocrates reports that Abbott's Libre Duo 10 Day system is the first wearable device to integrate ketone tracking with continuous glucose monitoring (CGM). This system provides real-time ketone trend data alongside... -
FDA Authorizes First Continuous Glucose-Ketone Monitoring Wearable for Diabetes Patients Aged 2 and Older: Libre Duo 10 Day
Patient Care Online USA Overview The FDA has authorized Abbott's Libre Duo 10 Day as the first continuous glucose-ketone monitoring system for diabetes patients aged 2 and older. This landmark approval significantly enhances patient safe... -
Abbott Wins FDA Nod for World’s First Dual Glucose-Ketone Sensor, Bolstering Diabetic Ketoacidosis Prevention
MDO Online USA Overview Abbott's Libre Duo 10 Day has received FDA authorization as the world's first Continuous Glucose Monitoring (CGM) system capable of continuously tracking both glucose and ketone levels. Developed to prevent diabet...
